FGF21 and metabolic dysfunction-associated steatotic liver disease: Sulforaphane suppresses hepatic steatosis in NAFLD mice by regulating lipid metabolism disorders via upregulation of the FGF21/FGFR1 pathway [39], reduces hepatic glucose production in patients with type 2 diabetes [40], and protects the liver against traumatic hemorrhagic shock by ameliorating apoptosis and inflammation by activating the Nrf2/HO-1 pathway [41].